Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 20, 2025 879 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline EMA Recommends Extension of Indications for Datopotamab Deruxtecan MOST POPULAR Tisagenlecleucel Is Safe and Effective in Pretreated Patients with Relapsed/Refractory Follicular... December 21, 2021 Preoperative ctDNA Levels Are Detectable in the Majority of Patients with... July 5, 2021 How targeted screening can help the NHS save lives from lung... November 23, 2022 Our sun safety messaging tours the UK with the NIVEA Sun... August 9, 2021 Load more HOT NEWS American Cancer Society Report Shows Economic, Racial Disparities in Cancer Outcomes ER-Low Positive Breast Cancer Shows Similar Clinical Behaviour and Response to... News digest – naked mole-rats, junk food deals, ovarian cancer drug... FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous...
